Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
XERS
XERS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
XERS News
Analyst Target Prices Indicate Potential for Pharmaceuticals ETF
Jan 29 2026
NASDAQ.COM
Xeris Anticipates 2025 Revenue of $292 Million, Exceeding Guidance
Jan 08 2026
Newsfilter
Outlook Therapeutics Inc Faces 60.9% Drop After FDA Response on ONS-5010
Jan 02 2026
Benzinga
Xeris Biopharma Shares Surge 7.59% as Competitor Corcept's FDA Approval Fails
Jan 01 2026
Fool
Xeris Biopharma Gains 7% as Corcept's FDA Setback Boosts Investor Sentiment
Jan 01 2026
NASDAQ.COM
Xeris Biopharma (XERS) Drops 9.3% Following XP-8121 Patent Milestone Announcement – Is the Bullish Outlook Still Valid?
Dec 06 2025
Yahoo Finance
Xeris Biopharma Holdings (XERS) Experiences Oversold Conditions
Dec 02 2025
NASDAQ.COM
Experts Predict FHLC Will Hit $81
Nov 07 2025
NASDAQ.COM
Oppenheimer Reaffirms Outperform Rating for Xeris Biopharma Holdings (XERS)
Oct 31 2025
NASDAQ.COM
Plus Therapeutics (PSTV) Posts Q3 Loss, Falls Short of Revenue Projections
Oct 31 2025
NASDAQ.COM
XERS Surpasses Average Analyst Price Target
Oct 16 2025
NASDAQ.COM
Outperform the Market with Zacks: Spotlight on MariMed, Xeris Biopharma, and Lam Research
Oct 13 2025
NASDAQ.COM
Xeris Pharmaceuticals Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Oct 03 2025
Yahoo Finance
Xeris Biopharma (XERS) Shows Strong Momentum: Is It a Good Investment?
Oct 03 2025
NASDAQ.COM
Reasons to Consider Xeris Biopharma (XERS) as a Strong Momentum Stock: Is It Time to Buy?
Sep 09 2025
NASDAQ.COM
XERS Crosses Above Average Analyst Target
Aug 08 2025
NASDAQ.COM
Show More News
